Preliminary results of a 10-year study examining a potential link between the diabetes drug Actos and bladder cancer have revealed that patients who take the drug over an extended period or at high doses showed an increased risk of developing this disease. The Food and Drug Administration is reviewing data from the study and plans to update the public when it has completed its review.
Actos is used for the treatment of patients with type-2 diabetes. Actos became the most widely prescribed diabetes treatment in the US after the former leader, Avandia, was linked to an increased risk of heart attack and cardiovascular problems.
After research suggested that Actos may increase a patient’s risk of bladder cancer, the FDA ordered the drug’s manufacturer to conduct a study to assess its cancer risk. Although the FDA says that it has not definitively concluded that Actos increases the risk of bladder cancer, the agency has advised patients to talk with their doctors if they experience any concerns about taking the drug.